Company Overview

60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of medicines for infectious diseases, with a particular emphasis on malaria and other diseases affecting travelers, military personnel, and populations in tropical or underserved regions. The company operates within the biopharmaceutical and anti-infective therapeutics industries and is publicly traded on the Nasdaq Capital Market under the ticker SXTP. Its primary commercial product is ARAKODA® (tafenoquine), an FDA-approved antimalarial drug indicated for malaria prophylaxis in adults.

The company’s business model combines commercialization of approved therapeutics with development-stage research programs targeting infectious diseases and immune-related conditions. Revenue generation has historically been driven primarily by product sales, licensing arrangements, and government-related opportunities associated with infectious disease preparedness. The company traces its origins to efforts focused on tropical medicine and military health applications, evolving into a publicly traded pharmaceutical enterprise with a portfolio centered on infectious disease therapeutics and strategic collaborations involving drug development and commercialization.

Business Operations

The company’s operations are centered around pharmaceutical product commercialization, clinical development, regulatory management, and intellectual property activities. Its principal operating focus includes ARAKODA®, while pipeline initiatives have explored additional uses for tafenoquine and other anti-infective compounds. The company has pursued opportunities involving malaria prevention, babesiosis treatment research, and viral disease-related therapeutic investigations. Revenue has been generated through product sales, government procurement opportunities, and collaborative arrangements tied to development programs and distribution activities.

Operationally, the company maintains a relatively streamlined corporate structure compared with larger pharmaceutical peers, relying on partnerships and outsourced manufacturing and development capabilities for portions of its operations. The company has collaborated with organizations involved in tropical medicine, military medicine, and pharmaceutical commercialization. Its activities include domestic U.S. operations as well as international commercial and regulatory engagement associated with malaria-related therapies. Data regarding certain partnership economics and long-term commercialization scale remain limited in public disclosures, and some operational details are inconclusive based on available public sources.

Strategic Position & Investments

The company’s strategic direction has emphasized expanding the commercial adoption of ARAKODA® while advancing additional therapeutic applications involving tafenoquine and related infectious disease programs. Management has highlighted opportunities in travel medicine, military health preparedness, and treatment areas with limited existing pharmaceutical competition. Strategic priorities have included strengthening distribution capabilities, increasing physician awareness, and pursuing clinical development initiatives tied to unmet medical needs in infectious disease treatment and prevention.

The company has also explored broader infectious disease and immune-response applications through research collaborations and internally managed development programs. Public filings and corporate disclosures indicate continuing interest in emerging infectious disease markets and government-supported healthcare initiatives. While the company has pursued licensing arrangements and development-stage investments, publicly available information does not indicate a large diversified subsidiary portfolio comparable to major pharmaceutical conglomerates. Information regarding certain investment outcomes and future commercialization timelines remains subject to regulatory and clinical development uncertainty.

Geographic Footprint

60 Degrees Pharmaceuticals, Inc. is headquartered in the United States, with corporate activities historically centered in the U.S. pharmaceutical and regulatory environment. The company’s market focus includes domestic travel medicine providers, military-affiliated healthcare channels, and infectious disease specialists. Its commercial footprint is closely tied to regions where malaria prevention and tropical disease management are relevant healthcare concerns.

Internationally, the company’s therapeutic focus inherently supports engagement with markets across Africa, Asia-Pacific, and other malaria-endemic regions, although its direct operational infrastructure outside the United States appears limited relative to multinational pharmaceutical companies. The company’s products and research activities have involved international regulatory, manufacturing, and distribution relationships connected to global infectious disease treatment and prevention efforts.

Leadership & Governance

The company was founded by Dr. Geoffrey Dow, who has played a central role in shaping its infectious disease and tropical medicine strategy. Leadership has consistently emphasized targeted pharmaceutical development for diseases with underserved patient populations, particularly where government health agencies, military organizations, and travel medicine specialists represent important stakeholders. Corporate governance and strategic messaging have focused on disciplined development spending, regulatory advancement, and niche-market commercialization opportunities.

Key executives and leadership figures include:

• Geoffrey Dow – Chief Executive Officer
• Andrew Dawson – Chief Operating Officer
• Corinne L. Le Goff – Director
• Charles H. Fischer IV – Director
• William P. Horan III – Director

Public company governance practices include oversight through a board of directors and compliance reporting under applicable U.S. securities regulations, including disclosures through SEC filings such as annual reports and registration statements. Certain executive role changes and committee assignments may vary over time based on subsequent corporate filings.